VideaHealth, the dental artificial intelligence (AI) platform, has received the US Food and Drug Administration (FDA) 510(k) approval for its Videa Perio Assist tool.

Videa Perio Assist is the company’s AI-powered interproximal bone level measurement tool, part of its dental AI platform Videa Assist, intended for periodontal disease assessment.

The AI-powered tool allows dentists and hygienists to easily measure interproximal bone level changes over time for patients aged 12 years and above.

Its Videa Perio Assist tool enables rapid and more accurate treatment recommendations and improved patient outcomes, said VideaHealth.

42 North Dental hygiene director Marlene Kacy said: “Videa Perio Assist has been a game-changer for our hygienists and dentists as it helps them more effectively identify signs of periodontal disease.

“VideaHealth not only empowers our team to make better treatment recommendations, but also its intuitive visualizations make it very easy for us to educate patients and explain our findings to them.”

According to CDC, nearly 50% of adults over age 30 have periodontal disease, which may contribute to chronic conditions such as diabetes, respiratory and heart disease.

Interproximal radiographic bone level (RBL) plays important role in diagnosis of periodontal disease alongside traditional periodontal probing.

VideaHealth said the use of its Videa Perio Assist AI algorithms for RBL allows dental clinicians to support their periodontal probing findings.

It also helps dentists and hygienists to provide findings in a highly engaging and visual presentation format, to help reverse and stop deterioration, said the company.

VideaHealth founder and CEO Florian Hillen said: “Since our inception, we’ve worked directly with dentists and DSOs to understand how AI can elevate care and move the dental industry forward.

“Periodontal disease has consistently been mentioned as a top concern, in part because of the challenges with interpreting its signs.

“Videa Perio Assist enables a more comprehensive and proactive approach to assessing interproximal RBL and monitoring periodontal disease.”